|
|
 |
|
Viewing report
|
|
|
|
The Future of Personalized Medicine: The Impact of Proteomics on Drug Discovery And Clinical Trial Design
Business Insights, Oct 2004
‘Personalized Medicine: The impact of proteomics on drug discovery and clinical trial design’ is a management report that analyses how proteomics will streamline drug development and lead to the more cost-effective development of niche personalized products of the future. Proteomics promises lower R&D costs and the opportunities of new revenue streams through the identification of new drug targets in the treatment of diseases such as cancer and Alzheimer's. Use this report to identify the most important technologies, their applications in drug discovery and clinical trial design and the leading companies driving development of this exciting new area. The pharmaceutical industry has so far been slow to take up proteomic technology and strategic alliances and acquisitions will be central to the pharmaceutical industry's uptake of proteomics. This report identifies the key technologies that will enable pharmaceutical companies to develop new niche products, improve drug attrition rates, increase the speed of clinical development and target new drug markets.
The key findings of this report:
- Proteomics has the potential to reduce drug development time and drug attrition rates. If total development time is reduced by three years and the number of successful NDAs doubled, R&D costs could be cut by as much as 30% per year.
- Companies investing in proteomics to target niche markets can reap considerable financial rewards as exemplified by Gleevec (Novartis) and Herceptin (Roche) which generated around $1bn in worldwide sales in 2003.
- There is a high unmet clinical need for early disease detection, such as in cancer and neurodegenerative diseases. The development of diagnostic tools using “biomarkers” has the potential to result in
better prognosis for patients and to satisfy this unmet need.
- More that $700m has been invested in proteomics companies by venture capitalists and through IPOs (Initial Public Offerings) in the last four years.
- As the main bottleneck in proteomics is the ability to analyze the colossal amount of data generated, it is essential for companies to invest heavily in bioinformatics.
This report answers the questions:
- What evidence is there that supports the impact of proteomics on pharmaceutical market productivity?
- Which companies have already invested in proteomics and what strategic alliances have been formed during the last 5 years?
- What role will proteomics have in the development of personalized medicine now and in the future?
- What is the role of bioinformatics in proteomics and what are the relative strengths and weaknesses of “free” and searchable databases on the worldwide web?
- What examples are there of the success of proteomics in the diagnosis and treatment of cancer, neurodegenerative diseases and cardiovascular diseases?
Reasons to purchase this report:
- Determine the most effective strategy of applying proteomics to all stages of the drug to development process to improve productivity and reduce R&D expenditure.
- Evaluate and learn from the acquisitions and strategic alliances formed between big pharmaceuticals and proteomics-based companies over the last five years.
- Discover where proteomics has already impacted the
identification of new drug targets and biomarkers for diagnosis screening.
- Highlight the potential long term cost savings associated with the integration of proteomic technologies in the pharmaceutical industry.
- Assess the freely available technologies and databases which will enable new players to harness the power of proteomics in the drug development process.
Customers who bought this item also bought
Personalized Medicine - Scientific and Commercial Aspects
Biomarkers in Drug Discovery - Optimizing Drug Discovery Timeline and Costs
Biomarkers - Advanced Technologies and Global Market (2009-2014)
Biomarkers in Drug Discovery - Earlier Usage of Biomarkers in Optimization Stage to Reduce Drug Attrition Rate Significantly
Biomarkers in Breast Cancer - 2011
Biomarkers in Late Stage Clinical Trials: Applications, Opportunities and Activities of Leading Players
Translational Medicine in Biopharmaceutical R&D: Enabling R&D Optimization and Early Detection of Potential Failures
Cancer Biomarkers: New Tools for Transforming Cancer Management
Drug Delivery in Cancer - Technologies, Markets and Companies
Companion Biomarkers in Drug Development
|
|
|
|
